Literature DB >> 3032669

A major metabolite of delta 1-tetrahydrocannabinol reduces its cataleptic effect in mice.

S Burstein, S A Hunter, V Latham, L Renzulli.   

Abstract

The results described here demonstrate that THC-induced catalepsy in mice can be substantially inhibited by the prior administration of delta 1-THC-7-oic acid, the major metabolite of THC in most species including humans. This raises the possibility that the intensity and duration of action of THC may depend to a large degree on the levels of this metabolite at the sites of action.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032669     DOI: 10.1007/BF01940427

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  8 in total

1.  Plasma and brain levels of delta 6-THC and seven monooxygenated metabolites correlated to the cataleptic effect in the mouse.

Authors:  A Ohlsson; M Widman; S Carlsson; T Ryman; C Strid
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980-10

2.  Prostaglandins and cannabis XV. Comparison of enantiomeric cannabinoids in stimulating prostaglandin synthesis in fibroblasts.

Authors:  S Burstein; S A Hunter; V Latham; R Mechoulam; D L Melchior; L Renzulli; R E Tefft
Journal:  Life Sci       Date:  1986-11-10       Impact factor: 5.037

3.  Prostaglandins and cannabis--XVI. Antagonism of delta 1-tetrahydrocannabinol action by its metabolites.

Authors:  S Burstein; S A Hunter; V Latham; L Renzulli
Journal:  Biochem Pharmacol       Date:  1986-08-01       Impact factor: 5.858

4.  The ring test: a quantitative method for assessing the 'cataleptic' effect of cannabis in mice.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  1972-12       Impact factor: 8.739

5.  Prostaglandins and cannabis--XIII. Cannabinoid-induced elevation of lipoxygenase products in mouse peritoneal macrophages.

Authors:  S Burstein; S A Hunter; K Ozman; L Renzulli
Journal:  Biochem Pharmacol       Date:  1984-08-15       Impact factor: 5.858

6.  The oral activity of delta'-tetrahydrocannabinol and its dependence on prostaglandin E2.

Authors:  J W Fairbairn; J T Pickens
Journal:  Br J Pharmacol       Date:  1979-11       Impact factor: 8.739

7.  Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication?

Authors:  L E Hollister; H K Gillespie; A Ohlsson; J E Lindgren; A Wahlen; S Agurell
Journal:  J Clin Pharmacol       Date:  1981 Aug-Sep       Impact factor: 3.126

8.  Prostaglandins and cannabis XIV. Tolerance to the stimulatory actions of cannabinoids on arachidonate metabolism.

Authors:  S Burstein; S A Hunter; L Renzulli
Journal:  J Pharmacol Exp Ther       Date:  1985-10       Impact factor: 4.030

  8 in total
  5 in total

1.  Brain disposition and catalepsy after intranasal delivery of loxapine: role of metabolism in PK/PD of intranasal CNS drugs.

Authors:  Yin Cheong Wong; Zhong Zuo
Journal:  Pharm Res       Date:  2013-06-07       Impact factor: 4.200

Review 2.  Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials.

Authors:  Summer Burstein
Journal:  AAPS J       Date:  2005-06-29       Impact factor: 4.009

3.  Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.

Authors:  Catherine F Moore; Elise M Weerts
Journal:  Psychopharmacology (Berl)       Date:  2021-10-15       Impact factor: 4.415

Review 4.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  The cannabinoid acids, analogs and endogenous counterparts.

Authors:  Sumner H Burstein
Journal:  Bioorg Med Chem       Date:  2014-04-01       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.